Mode
Text Size
Log in / Sign up

Omission of completion axillary lymph node dissection shows no difference in axillary recurrence ratesSkipping certain lymph node surgery shows no difference in recurrence

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that omitting completion axillary lymph node dissection in selected ypN+ patients shows no significant difference in recurrence.

This meta-analysis evaluated the impact of omitting completion axillary lymph node dissection (ALND) compared to performing it in patients with biopsy-proven node-positive breast cancer who had residual nodal disease (ypN+) after neoadjuvant therapy. The analysis included a total of 4670 patients to compare axillary recurrence and survival outcomes.

The primary finding was no clear difference in axillary recurrence between the two groups (RR 1.09; 95% CI, 0.47-2.52; P =.80). Reported recurrence rates were 0.37%-5.7% for patients without ALND and 0.4%-4.8% for those with ALND. The authors noted that omitting completion ALND in selected ypN+ patients treated with RNI appears to yield low axillary recurrence and similar survival outcomes while potentially reducing surgical morbidity.

Limitations of the evidence include moderate heterogeneity (I2 = 46%) and the fact that the data were derived from nonrandomized comparative studies. Clinical application should consider these limitations when determining surgical management for patients with residual nodal disease.

How this fits prior evidence

This finding addresses a gap in surgical management for patients with residual nodal disease (ypN+) after neoadjuvant therapy. While previous coverage has focused on diagnostic tools like artificial intelligence and supportive care such as combined exercise for cancer-related fatigue, this meta-analysis specifically addresses the surgical necessity of completion axillary lymph node dissection in the context of axillary recurrence.

When a patient is diagnosed with breast cancer that has spread to the lymph nodes, surgery is a critical step. Doctors often have to decide how much of the lymph node area needs to be removed. This decision is vital because the surgery can be physically demanding, but it must also ensure that the cancer does not return in the armpit area.

Researchers looked at data from 4,670 patients who had already received certain treatments before surgery. They compared patients who had a full lymph node removal to those who did not. The results showed no clear difference in the rate of cancer returning in the armpit between the two groups. Both groups showed very low rates of recurrence, with figures staying under 6% in both cases.

While the results are encouraging, the evidence comes from non-randomized studies, which means the groups were not perfectly balanced from the start. However, the findings suggest that for certain patients, skipping the extra surgery might reduce physical complications without increasing the risk of the cancer coming back. You should talk to your doctor to see if this approach fits your specific treatment plan.

What this means for you:
Skipping certain lymph node surgeries after specific treatments may not increase the risk of cancer returning.

Common questions

Does skipping the full lymph node surgery increase the risk of cancer coming back?

The study of 4,670 patients found no clear difference in the rate of cancer returning in the armpit. The recurrence rates were very low for both groups, ranging between 0.37% and 5.7% for those who did not have the full surgery, and 0.4% to 4.8% for those who did.

Who is this finding relevant for?

This finding is relevant for patients with biopsy-proven node-positive breast cancer who have already received neoadjuvant therapy (treatment before surgery) and still have some remaining disease in the lymph nodes at the time of surgery.

Is this finding certain enough to change treatment?

The evidence is based on non-randomized studies, which means there is some uncertainty in the data. Because of this, you should discuss these specific findings with your surgical team to determine the best plan for your individual case.

Study Details

Study typeMeta analysis
Sample sizen = 4,670
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
The oncologic value of axillary lymph node dissection (ALND) for residual node-positive (ypN+) breast cancer after neoadjuvant therapy is uncertain when regional nodal irradiation (RNI) is routinely used. We systematically reviewed comparative evidence on locoregional control and survival outcomes with omission versus completion of ALND. PubMed/MEDLINE, Embase, and Cochrane Central were searched from 2000 to 2025 for English-language studies comparing completion ALND with omission of ALND (sentinel lymph node biopsy and/or targeted axillary dissection) among patients with biopsy-proven node-positive breast cancer treated with neoadjuvant therapy who had residual nodal disease at surgery. Two reviewers screened studies and extracted outcomes. We identified 445 initial records for screening and review. Five nonrandomized comparative studies, including 4670 patients, met inclusion criteria and directly compared ypN+ outcomes by axillary surgery extent. In cohorts where RNI was commonly administered, axillary recurrence was uncommon (0.37%-5.7% without ALND and 0.4%-4.8% with ALND). Meta-analysis of comparative studies showed no clear difference in axillary recurrence with omission versus completion of ALND (pooled RR 1.09, 95% CI, 0.47-2.52; P = .80), with moderate heterogeneity (I² = 46%). In selected ypN+ patients treated with RNI, omission of completion ALND appears to yield low axillary recurrence and similar survival outcomes while potentially reducing surgical morbidity. Randomized trials and long-term results of prospective studies are needed to further guide axillary management of patients with residual nodal burden after neoadjuvant therapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.